Ocular's lead product fails in second PhIII
Ocular Therapeutix's sank on 7 April following mediocre results from a second Phase III trial of the company's lead product candidate, OTX-DP (sustained release dexamethasone).
Ocular Therapeutix's sank on 7 April following mediocre results from a second Phase III trial of the company's lead product candidate, OTX-DP (sustained release dexamethasone).